Advertisement

Related Videos

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Advertisement

Advertisement




Jul
30
Today In Oncology
Germline Genetic Variants Associated With CAR T-Cell Therapy Safety and Efficacy in Hematologic Malignancies
FDA Approves SimpleScreen CRC Blood-Based Screening Test for Colorectal Cancer
MMUD vs MRD Transplantation in the Posttransplant Cyclophosphamide Era
Global Breast Cancer Survival Estimates: WHO Analysis
Concurrent Palliative Care Remains Underused Among Young Adults With Advanced Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo